Brought to you by 
Sientra nets $108 mm in FOPO
08 May 2018
Executive Summary
Sientra Inc. (medical aesthetics) netted $108mm through an upsized public offering of 8.5mm shares (including the overallotment) at $13.50. The company (which originally expected to gross $75mm through the offer) will use the proceeds to launch sales and marketing initiatives, expand commercialization in the US and globally, fund R&D efforts, and potentially for future product or company acquisitions. Earlier this month Sientra announced FDA approval for its Opus silicone gel breast implants (which will be manufactured in the US by partner Vesta), triggering a $10mm tranche of term debt under its separate July 2017 credit facility with MidCap Financial.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sientra nets $108 mm in FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice